World

New Diabetes and Weight Loss Pill Foundayo Launched in UK Pharmacies

The new pill Foundayo, which treats diabetes and aids weight loss, is now available on prescription in UK pharmacies amidst warnings about counterfeit products.

24 August 2026Tagblick Newsdesk

AI-generatedWritten by an AI system, editorially responsible — how we work

Archive photo: New Diabetes and Weight Loss Pill Foundayo Launched in UK Pharmacies — Archive photoPhoto: Archives New Zealand from New Zealand · Wikimedia Commons · CC BY-SA 2.0

Foundayo, a new daily pill designed to manage diabetes and assist with weight loss, became available in pharmacies across the UK starting Monday. The launch marks the UK's position as the first country in Europe to approve this medication.

According to reports, Foundayo will be accessible only through private prescriptions, allowing individuals seeking assistance for diabetes and weight management to obtain it from pharmacists.

Pharmacists have indicated that the availability of this medication is a positive development for those unable to use traditional weight-loss injections. They emphasize that it could provide an alternative treatment option for these patients.

However, alongside the rollout of Foundayo, pharmacists expressed concerns regarding an increase in counterfeit versions of GLP-1 tablets. They cautioned consumers about the risks associated with unlicensed and fake products that may enter the market.

The issue of counterfeit medications remains a significant problem in the pharmaceutical sector, highlighting the importance of obtaining prescriptions from legitimate sources to ensure safety and efficacy. Pharmacists are urging patients to be vigilant when purchasing medications.

As the healthcare community adapts to the introduction of Foundayo, the attention will also remain on strategies to combat the prevalence of counterfeit drugs, ensuring that patients receive quality treatment. This dual focus is vital to support both the effective management of diabetes and the integrity of pharmacy practices.

This item was written by an AI system on the basis of the headlines and short teasers of the independently operating newsrooms named below. We disclose this under Art. 50(4), second subparagraph, of Regulation (EU) 2024/1689 (AI Act). Before publication we check origin and verifiability — anything that appears in only one place is not published — as well as language, substance and legally sensitive content. No separate substantive review of each individual item by a natural person takes place; we therefore do not rely on the exemption in Art. 50(4), second subparagraph, of the AI Act. Editorial responsibility for this publication rests with the person named in the imprint (§ 18 Abs. 2 MStV). Please report errors to [email protected] — we will correct or remove the item. Full reports are available from the sources listed.